Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to
treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food
and Drug Administration (FDA) to treat HIV infection. When darunavir and ritonavir are given
with pravastatin, they can increase the blood levels of pravastatin. The degree of this
interaction varies from person to person. The way that darunavir and ritonavir interact with
pravastatin may be affected by a person's genetic make-up. Genetic factors (or DNA) are those
that people are born with and that make each person unique. Genetic differences are the
reason why one person's body traits such as height and hair color are different from another
person's body traits. Genetic differences can also affect the way a medication works in the
body or the way two medications interact in the body. The purpose of this clinical study is
to determine if a person's genetic make-up affects the way darunavir and ritonavir interact
with pravastatin in the body.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA